Two new RSV vaccine candidates, made by Pfizer and GlaxoSmithKline, could become the world’s first approved shots against the common respiratory syncytial virus (RSV). The FDA, which typically follows the committee’s recommendations, is expected to decide on approval in May, ahead of RSV’s typical winter surge.
Source: www.cnn.com
Related posts:
Busy developer eyes new apartment complex near downtown Oakland
NReal AR glasses set to launch this spring in UK
Despite working in a failed system, officers offer a ray of hope
Eleven pounds of meth seized in Newark drug bust
EU leaders mull tougher sanctions against Iran at a summit as Zelenskyy pleads for more support